These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer. Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629 [TBL] [Abstract][Full Text] [Related]
9. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364 [TBL] [Abstract][Full Text] [Related]
10. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide. Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342 [TBL] [Abstract][Full Text] [Related]
11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma. Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698 [TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer. Naumann RW; Alvarez RD; Omura GA; Segars E; Kilgore LC; Partridge EE Gynecol Oncol; 1998 Dec; 71(3):450-3. PubMed ID: 9887248 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481 [TBL] [Abstract][Full Text] [Related]